International Clinical Trial: HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07824934) titled 'HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors' on Sept. 5.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sunshine Lake Pharma Co., Ltd.

Condition: Advanced Malignant Solid Tumors

Intervention: Drug: HEC-921 Drug: HEC-921 Drug: Oxaliplatin Drug: Capecitabine

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: September 2026

Target Sample Size: 110

Countries o...